Exosome LRRK2 in Predicting Parkinson's Disease Phenotypes (U01)

Andrew West, Ph.D.
Andrew West, PhD
University of Alabama (Birmingham, Alabama)


Over the last several years, Dr. West’s laboratory has identified that levels of pS1292-LRRK2 isolated from urine and CSF exosomes are predictive of the risk for Parkinson’s Disease (PD) in G2019S-LRRK2 carriers, as well as the severity of the disease in idiopathic PD patients.  This project will focus on whether measurements of exosomal isolated pS1292-LRRK2 can act as a diagnostic and/or prognostic biomarker for LRRK2 mutation carriers and idiopathic PD cases.  Preliminary data indicate that pS1292-LRRK2 may be a prognostic biomarker for idiopathic PD in regards to the rate of cognitive decline in mid to late PD cases and in regards to the rate of early motor symptom development and time to L-dopa medication in de novo cases.  This project will utilize biosamples and clinical data associated with the LRRK2 Cohort, the JHMI PDBP study and the MJFF PPMI study.


There is a critical need for quantitative biomarkers that predict Parkinson disease (PD) susceptibility and progression. Such biomarkers would aid the development of new therapies that slow or halt disease. PD has a clear genetic component that contributes to disease susceptibility. One gene in particular, leucine-rich repeat kinase 2 (LRRK2), harbors pathogenic missense mutations prevalent in some populations. LRRK2 is further linked to PD susceptibility through genome-wide association studies. Pathogenic LRRK2 mutations upregulate LRRK2 kinase activity and increase levels of the auto phosphorylated residue serine S1292 (pS1292). In our previous project Exploratory Laboratory and Analysis Projects in PDBP (U18 NS082132), we focused our efforts on analyzing and measuring LRRK2 in clinical samples. We discovered that auto phosphorylated LRRK2 (pS1292-LRRK2) could be detected and quantified in exosome fractions from both cerebral-spinal fluid (CSF) and urine. We found elevated levels (~5 fold) of pS1292-LRRK2 in urinary exosomes from G2019S-LRRK2 mutation carriers with PD. In G2019S-LRRK2 mutation carriers, pS1292-LRRK2 levels successfully predicting clinical PD manifestation. We further analyzed pS1292-LRRK2 in a large cohort of cases and controls (n=160) from the University of Alabama at Birmingham Parkinson's Disease Biomarker Program (UAB PDBP) and found that pS1292-LRRK2 levels predicted PD phenotypes in patients. Here we will determine the potential of exosome pS1292-LRRK2, purified from urine and CSF, in predicting PD susceptibility and progression in both early and mid-stage idiopathic PD cases as well as in LRRK2 mutation carriers. Project success will include the discovery of novel insights into the role of LRRK2 in the pathogenesis of PD and the development of a novel biomarker (exosome pS1292-LRRK2) that may predict PD manifestation in LRRK2 mutation carriers. The successful prediction of LRRK2 mutation carriers that will go on to develop PD would aid in future clinical trial design for LRRK2-directed therapies. Finally, we predict that the novel biomarker exosome pS1292- LRRK2 may help stratify idiopathic PD patients that will experience rapid progression of PD symptoms from those with more benign disease courses. Identification of PD cases with a poor prognosis would assist physicians in making treatment choices and clinical trial design for novel neuroprotective therapies.


Goals of this project:

1. Isolation of exosomes from urine and CSF samples from the LRRK2 cohort and measurement of pS1292-LRRK2 levels using Western blot analysis.

2. Isolation of exosomes from urine and CSF samples from the JHMI PDPB cohort (cross-sectional and longitudinal) to determine if levels of pS1292-LRRK2 correspond to PD non-motor disease severity.

3. Determine if western blot analysis using LRRK2 mouse monoclonal N241A/34 (Antibodies Inc), and pS1292-LRRK2 rabbit monoclonal (Abcam MJFR-19 LRRK2) can be developed into a SiMoA assay in collaboration with Dr. David Walt.